Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.
Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system (CNS), to develop a gene therapy for Parkinson’s disease.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.